Eptapirone

Catalog No.S0113 Batch:S011301

Print

Technical Data

Formula

C16H23N7O2

Molecular Weight 345.40 CAS No. 179756-58-2
Solubility (25°C)* In vitro DMSO 69 mg/mL (199.76 mM)
Ethanol 39 mg/mL (112.91 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Eptapirone (F11440) is a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.The affinity (pKi) of F11440 for 5-HT1A binding sites is 8.33.
Targets
5-HT1A [1]
(in the 5-HT1A binding assay)
8.33(pKi)
In vitro

The affinity of Eptapirone for 5-HT1A binding sites (pKi, 8.33) is higher than that of buspirone (pKi, 7.50), and somewhat lower than that of flesinoxan (pKi, 8.91). In HeLa cells expressing human 5-HT1A receptors, Eptapirone decreases the forskolin-induced increase in AMP, and, based on its maximal effect, is found to have an intrinsic activity of 1.0 relative to that of 5-HT, which is significantly higher than that of buspirone (0.49), ipsapirone (0.46) and flesinoxan (0.93).[1]

In vivo

In vivo, Eptapirone (F11440) is 4- to 20-fold more potent than flesinoxan, and 30- to 60-fold more potent than buspirone, in exerting 5-HT1A agonist activity at pre- and postsynaptic receptors in rats (measured by, for example, its ability to decrease hippocampal extracellular serotonin (5-HT) levels and to increase plasma corticosterone levels, respectively). Eptapironeproduced anxiolytic- and antidepressant-like effects in animal models (i.e., increased punished responding in a pigeon conflict procedure and decreased immobility in a rat forced swimming test, respectively) that are more substantial than those of buspirone, ipsapirone and flesinoxan. [1]

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    HeLa cells

  • Concentrations

    --

  • Incubation Time

    10 min

  • Method

    Cells are preincubated with DMEM, 10 mM HEPES for 10 min at room temperature. Drugs, at concentrations ranging from 0.1 nM to 100 M, and appropriate vehicle controls, are then added in DMEM, 10 mM HEPES, 100 M forskolin and 100 M IBMX to the cells. Antagonists are added at the same time as the agonists. At the end of the treatment (10 min, room temperature), the reaction is stopped by aspiration of the medium and addition of 0.1 N HCl. Cellular extract is diluted 1:500 or 1:400 in radioimmunoassay buffer, and cAMP content is measured by using a commercially available kit.

Animal Study:

[1]

  • Animal Models

    Male Sprague-Dawley rats (160 to 200 g); Male Dunkin-Hartley guinea pigs (310 to 490 ); Male White Carneau pigeons (500 to 650 g)

  • Dosages

    0.16 mg/kg

  • Administration

    i.p.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.